Claims for Patent: 7,902,239

Summary for Patent: 7,902,239

Title:	Diaminotriazoles useful as inhibitors of protein kinases
Abstract:	The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Inventor(s):	Pierce; Albert C. (Cambridge, MA), Arnost; Michael (North Andover, MA), Davies; Robert J. (Arlington, MA), Forster; Cornelia J. (Pelham, NH), Galullo; Vincent (South Grafton, MA), Grey, Jr.; Ronald (Cambridge, MA), Ledeboer; Mark (Acton, MA), Tian; Shi-Kai (Waltham, MA), Xu; Jinwang (Framingham, MA), Binch; Hayley (Harwell, GB), Ledford; Brian (Attleboro, MA), Messersmith; David (Somerville, MA), Nanthakumar; Suganthi (Newton, MA), Jayaraj; Andrew (Needham, MA), Henkel; Greg (Carlsbad, CA), Salituro; Francesco G. (Marlboro, MA), Wang; Jian (Newton, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	11/774,702
Patent Claims:	1. A method of treating or lessening the severity of a proliferative disorder selected from acute myelogenous leukemia, acute promyelocytic leukemia, or acute lymphocytic leukemia in a patient comprising administering a compound of formula II or II': ##STR01352## or a pharmaceutical composition comprising said compound, in an amount sufficient to treat or lessen the severity of said proliferative disorder in said patient, wherein R.sup.1 is hydrogen; R.sup.2 is Ar', wherein Ar.sup.1 is a phenyl group substituted with x independent occurrences of Q-R.sup.X, wherein x is 1-5; Q is a bond or is a C.sub.1-C.sub.6 alkylidene chain wherein up to two methylene units of Q are optionally replaced by --NR--, --S--, --O--, --CS--, --CO.sub.2--, --OCO--, --CO--, --COCO--, --CONR--, --NRCO--, --NRCO.sub.2--, --SO.sub.2NR--, --NRSO.sub.2--, --CONRNR--, --NRCONR--, --OCONR--, --NRNR--, --NRSO.sub.2NR--, --SO--, --SO.sub.2--, --PO--, --PO.sub.2--, or --POR--; and each occurrence of R.sup.X is independently R', halogen, NO.sub.2, CN, OR', SR', N(R').sub.2, NR'COR', NR'CONR'.sub.2, NR'CO.sub.2R', COR', CO.sub.2R', OCOR', CON(R').sub.2, OCON(R').sub.2, SOR', SO.sub.2R', SO.sub.2N(R').sub.2, NR'SO.sub.2R', NR'SO.sub.2N(R').sub.2, COCOR', or COCH.sub.2COR', wherein at least one Q-R.sup.X is not hydrogen; R.sup.3 is bonded to the nitrogen atom in either the 1- or 2-position of the ring and is Ar.sup.2, wherein Ar.sup.2 is an optionally substituted aryl group selected from pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thiophenyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, or an 8-12 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein said aryl group is optionally substituted with y occurrences of Z-R.sup.Y; wherein y is 0-5, Z is a bond or is a C.sub.1-C.sub.6 alkylidene chain wherein up to two methylene units of Z are optionally replaced by --NR--, --S--, --O--, --CS--, --CO.sub.2--, --OCO--, --CO--, --COCO--, --CONR--, --NRCO--, --NRCO.sub.2--, --SO.sub.2NR--, --NRSO.sub.2--, --CONRNR--, --NRCONR--, --OCONR--, --NRNR--, --NRSO.sub.2NR--, --SO--, or --SO.sub.2--; and each occurrence of R.sup.Y is independently R', halogen, NO.sub.2, CN, OR', SR', N(R').sub.2, NR'COR', NR'CONR'.sub.2, NR'CO.sub.2R', COR', CO.sub.2R', OCOR', CON(R').sub.2, OCON(R').sub.2, SOR', SO.sub.2R', SO.sub.2N(R').sub.2, NR'SO.sub.2R', NR'SO.sub.2N(R').sub.2, COCOR', or COCH.sub.2COR'; and each occurrence of R is independently hydrogen or an optionally substituted C.sub.1-6 aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted group selected from a C.sub.1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R and R', two occurrences of R, or two occurrences of R', are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 2. The method of claim 1, wherein said compound has one of the formulae: ##STR01353## ##STR01354## 3. The method of claim 2, wherein x is 1-3; y is 0-3; and each occurrence of QR.sup.X or ZR.sup.Y is independently R', halogen, CN, NO.sub.2--N(R').sub.2, --CH.sub.2N(R').sub.2, --OR', --CH.sub.2OR', --SR', --CH.sub.2SR', --COOR', --NRCOR', --CON(R').sub.2, --SO.sub.2N(R').sub.2, --CONR(CH.sub.2).sub.2N(R').sub.2, --CONR(CH.sub.2).sub.3N(R').sub.2, --CONR(CH.sub.2).sub.4N(R').sub.2, --O(CH.sub.2).sub.2OR', --O(CH.sub.2).sub.3OR', --O(CH.sub.2).sub.4OR', --O(CH.sub.2).sub.2N(R').sub.2, --O(CH.sub.2).sub.3N(R').sub.2, or --O(CH.sub.2).sub.4N(R').sub.2. 4. The method of claim 3, wherein QR.sup.X or ZR.sup.Y groups are each independently Cl, Br, F, CF.sub.3, Me, Et, CN, --COOH, --N(CH.sub.3).sub.2, --N(Et).sub.2, --N(iPr).sub.2, --O(CH.sub.2).sub.2OCH.sub.3, --CONH.sub.2, --COOCH.sub.3, --OH, --CH.sub.2OH, --NHCOCH.sub.3, --SO.sub.2NH.sub.2, methylenedioxy, ethylenedioxy, --O(CH.sub.2).sub.2N-morpholino, --O(CH.sub.2).sub.3N-morpholino, --O(CH.sub.2).sub.4N-morpholino, --O(CH.sub.2).sub.2N-piperazinyl, --O(CH.sub.2).sub.3N-piperizinyl, --O(CH.sub.2).sub.4N-piperizinyl, --NHCH(CH.sub.2OH)phenyl, --CONH(CH.sub.2).sub.2N-morpholino, --CONH(CH.sub.2).sub.2N-piperazinyl, --CONH(CH.sub.2).sub.3N-morpholino, --CONH(CH.sub.2).sub.3N-piperazinyl, --CONH(CH.sub.2).sub.4N-morpholino, --CONH(CH.sub.2).sub.4N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.2N-morpholino, --SO.sub.2NH(CH.sub.2).sub.2N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.3N-morpholino, --SO.sub.2NH(CH.sub.2).sub.3N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.4N-morpholino, --SO.sub.2NH(CH.sub.2).sub.4N-piperazinyl, where each of the foregoing phenyl, morpholino, piperazinyl, or piperidinyl groups is optionally substituted, or an optionally substituted group selected from C.sub.1-4alkoxy, phenyl, phenyloxy, benzyl, piperidinyl, piperazinyl, morpholino, or benzyloxy. 5. The method of claim 1, wherein said compound is selected from the following: ##STR01355## ##STR01356## ##STR01357## ##STR01358## ##STR01359## ##STR01360## ##STR01361## ##STR01362## ##STR01363## ##STR01364## ##STR01365## ##STR01366## ##STR01367## ##STR01368## ##STR01369## ##STR01370## ##STR01371## ##STR01372## ##STR01373## ##STR01374## ##STR01375## ##STR01376## ##STR01377## ##STR01378## ##STR01379## ##STR01380## ##STR01381## ##STR01382## ##STR01383## ##STR01384## ##STR01385## ##STR01386## ##STR01387## ##STR01388## ##STR01389## ##STR01390## ##STR01391## ##STR01392## ##STR01393## ##STR01394## ##STR01395## ##STR01396## ##STR01397## ##STR01398## ##STR01399## ##STR01400## ##STR01401## ##STR01402## ##STR01403## ##STR01404## ##STR01405## ##STR01406## ##STR01407## ##STR01408## ##STR01409## ##STR01410## ##STR01411## ##STR01412## ##STR01413## ##STR01414## ##STR01415## ##STR01416## ##STR01417## ##STR01418## ##STR01419## ##STR01420## ##STR01421## ##STR01422## ##STR01423## ##STR01424## ##STR01425## ##STR01426## ##STR01427## ##STR01428## ##STR01429## ##STR01430## ##STR01431## ##STR01432## ##STR01433## ##STR01434## ##STR01435## ##STR01436## ##STR01437## ##STR01438## ##STR01439## ##STR01440## ##STR01441## ##STR01442## ##STR01443## ##STR01444## ##STR01445## ##STR01446## ##STR01447## ##STR01448## ##STR01449## ##STR01450## ##STR01451## ##STR01452## ##STR01453## ##STR01454## ##STR01455## ##STR01456## ##STR01457## ##STR01458## ##STR01459## ##STR01460## ##STR01461## ##STR01462## ##STR01463## ##STR01464## ##STR01465## ##STR01466## ##STR01467## ##STR01468## ##STR01469## ##STR01470## ##STR01471## ##STR01472## ##STR01473## ##STR01474## ##STR01475## ##STR01476## ##STR01477## ##STR01478## ##STR01479## ##STR01480## ##STR01481## ##STR01482## ##STR01483## ##STR01484## ##STR01485## ##STR01486## ##STR01487## ##STR01488## ##STR01489## ##STR01490## ##STR01491## ##STR01492## ##STR01493## ##STR01494## ##STR01495## ##STR01496## ##STR01497## ##STR01498## ##STR01499## ##STR01500## ##STR01501## ##STR01502## ##STR01503## ##STR01504## ##STR01505## ##STR01506## ##STR01507## ##STR01508## ##STR01509## ##STR01510## ##STR01511## ##STR01512## ##STR01513## ##STR01514## ##STR01515## ##STR01516## ##STR01517## ##STR01518## ##STR01519## ##STR01520## ##STR01521## ##STR01522## ##STR01523## 6. The method of claim 1, wherein said method further comprises administering to said patient an additional therapeutic agent selected from mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide, methotrexate, 6-mercaptopurine, 5-fluorouracil, cytarabile, gemcitabine, vinblastine, vincristine, vinorelbine, paclitaxel, etoposide, irinotecan, topotecan, doxorubicin, bleomycin, mitomycin, carmustine, lomustine, cisplatin, carboplatin, asparaginase, tamoxifen, leuprolide, flutamide, megestrol, imatinib mesylate, adriamycin, dexamethasone, or cyclophosphamide.

Details for Patent 7,902,239

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2022-11-15